OC
TLOG

Oppenheimer & Co’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Oppenheimer & Co’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,500
Closed -$48K – 1535
2014
Q3 		$48K Buy
+11,500
New +$53.6K ﹤0.01% 1390
2014
Q1 		– Sell
-1,072,115
Closed -$10.2M – 1511
2013
Q4 		$10.2M Buy
+1,072,115
New +$8.36M 0.33% 57

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Oppenheimer & Co's TLOG Position: Q4 2014 in Review

Oppenheimer & Co sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2014, closing a stake of 11,500 shares — an estimated $48K sold.

Oppenheimer & Co first reported a position in TLOG in Q4 2013 and held it in 2 quarters. The position peaked at $10.2M in Q4 2013. 31 funds tracked by Wall St. Rank hold TLOG as of Q4 2014.

  • Oppenheimer & Co reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 11,500 TetraLogic Pharmaceuticals Corporation shares in Q4 2014, an estimated $48K.
  • Oppenheimer & Co first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 2 quarters.
  • Oppenheimer & Co's TetraLogic Pharmaceuticals Corporation position peaked at $10.2M in Q4 2013.
  • 31 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2014.

Based on Oppenheimer & Co's 13F filing for Q4 2014, filed 10 Feb 2015.